Brazil acts to spur domestic production of key medicines

Brazil announced a major initiative Thursday to spur domestic production of medicines and equipment to combat diseases such as Alzheimers.

Alexandre Padilha said the plans call for major government investments in the field, public-private partnerships to produce drugs, and fast-tracking patents and registration of products crucial to .

He estimated that the measures would lead to savings of 354 million reais ($179 million) over five years, because the government currently imports most of the medicines involved and makes them available to the national health system.

"To produce here in Brazil means a saving for the government and the consumer," the Padilha said. "These products can lead to price reductions for the consumer."

He made the announcement at a meeting hosted by the Federation of Industries of the State of Sao Paolo.

He said the would extend seven billion reais ($3.5 billion) in credits to Brazilian firms involved in innovative health projects and pump another 1.3 billion reais ($651 million) into the infrastructure of public laboratories.

He said key regulatory bodies—the National Health Surveillance Agency ANVISA, the National Institute of Intellectual Property (INPI) and the Brazilian Association of Technical Norms (ABNT)—would sign agreements aimed at speeding up the process for obtaining patents and registering products.

(c) 2013 AFP

Citation: Brazil acts to spur domestic production of key medicines (2013, April 12) retrieved 18 April 2024 from https://medicalxpress.com/news/2013-04-brazil-spur-domestic-production-key.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Brazil moves to combat 'crack epidemic'

 shares

Feedback to editors